Catalyst
Slingshot members are tracking this event:
Acorda reached a settlement agreement in which Par Pharmaceutical will be permitted to market its generic drug version of Ampyra (dalfampridine), but only in 2027, or potentially sooner under certain circumstances
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACOR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Settlement Agreement, Marketing Permission, Generic Drug, Ampyra, Dalfampridine
